

US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs

Lyon (France), October 12th, 2022 – 1h15pm - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the U.S. Environmental Protection Agency (US EPA) has approved the tolerance exemption for the biocontrol active substance on foodstuffs.

Following its positive pre-decision (see Press Release of September 29, 2022), the EPA has approved the exemption of a maximum permissible level (tolerance exemption) for the lysate of *Willaertia magna* C2c Maky, corresponding to the regulatory threshold of pesticide residue concentration, above which the marketing of a food product is no longer allowed.

The decision of the US EPA can be seen on the federal register:

<https://www.federalregister.gov/documents/2022/10/12/2022-22045/lysate-of-willaertia-magna-c2c-maky-exemption-from-the-requirement-of-a-tolerance>

The Company is still awaiting the final decision on the authorization of the biocontrol active substance by the EPA, which is expected before the end of October.

About Amoéba :

Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba *Willaertia magna* C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion (1), as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (2) in the United States. The commercialisation of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com.

1. *marketsandmarkets.com*, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

2. *Amoéba data*

Contacts:

Amoéba

Valérie FILIATRE
Deputy General Manager
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus

Investor & Press Relations
Nicolas HELIN / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.